HALO News and Press, Halozyme Therapeutics Inc. From 01/19/24

2024-01-19 09:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-18 08:36:41 ET More on Lipocine Seeking Alpha’s Quant Rating on Lipocine Historical earnings data for Lipocine Financial information for Lipocine For further details see: Lipocine licenses Tlando testosterone therapy to Verity Pharma

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis PR Newswire VYVDURA® provides patients with option for self-administration SAN DI...

2024-01-18 07:00:29 ET More on Argenx SE, Bayer, etc. Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) argenx: Back To Earth After 2 Clinical Tria...

2024-01-17 08:53:24 ET More on Halozyme Therapeutics Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation ...

2024-01-16 12:40:46 ET More on Halozyme Therapeutics Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation ...

Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) PR Newswire SAN DIEGO , Jan. 16, 2024 /PRNewswire/ -- Halozyme Therape...

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types PR Newswire Reduces treatment time by approximately 80% compared to standard ...

Halozyme to Host Investor Business Forum and Long-Term Outlook Call PR Newswire SAN DIEGO , Jan. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it will host an Investor Business Forum and Long-Term Outlook Call ...

2024-01-08 17:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...